Datopotamab deruxtecan plus Imfinzi showed promising clinical activity in the first-line advanced non-small cell lung cancer setting in TROPION-Lung04 Phase Ib trial
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan plus Imfinzi with or without chemotherapy demonstrated objective response rates of 77% and 50% and disease control rates of 92% and 93%, respectively. Three ongoing pivotal trials are evaluating datopotamab deruxtecan and immune checkpoint inhibitor combinations in 1st-line advanced non-small cell lung cancer. Initial results from the TROPION-Lung04 Phase Ib trial showed that datopotamab deruxtecan (Dato-DXd) in combination with Imfinzi (durvalumab), an anti-